Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Immunome Inc’s stock clocked out at $18.32, down -0.54% from its previous closing price of $18.42. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 0.81 million shares were traded. IMNM stock price reached its highest trading level at $18.54 during the session, while it also had its lowest trading level at $17.855.
Ratios:
To gain a deeper understanding of IMNM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.90 and its Current Ratio is at 8.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on December 01, 2025, initiated with a Buy rating and assigned the stock a target price of $36. On September 22, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $26.
On September 05, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $26.Craig Hallum initiated its Buy rating on September 05, 2025, with a $26 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when BIENAIME JEAN JACQUES bought 5,000 shares for $9.38 per share. The transaction valued at 46,900 led to the insider holds 36,415 shares of the business.
BIENAIME JEAN JACQUES bought 7,800 shares of IMNM for $60,684 on Mar 25 ’25. The Director now owns 31,415 shares after completing the transaction at $7.78 per share. On Mar 26 ’25, another insider, SIEGALL CLAY B, who serves as the President and CEO of the company, bought 137,100 shares for $7.29 each. As a result, the insider paid 999,459 and bolstered with 806,736 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 1680132352 and an Enterprise Value of 1411506304. For the stock, the TTM Price-to-Sale (P/S) ratio is 173.57 while its Price-to-Book (P/B) ratio in mrq is 6.37. Its current Enterprise Value per Revenue stands at 145.832 whereas that against EBITDA is -6.9.
Stock Price History:
The Beta on a monthly basis for IMNM is 2.18, which has changed by 0.36041355 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $19.16, while it has fallen to a 52-week low of $5.15. The 50-Day Moving Average of the stock is 19.61%, while the 200-Day Moving Average is calculated to be 73.85%.
Shares Statistics:
It appears that IMNM traded 1.49M shares on average per day over the past three months and 1165060 shares per day over the past ten days. A total of 91.71M shares are outstanding, with a floating share count of 89.10M. Insiders hold about 2.85% of the company’s shares, while institutions hold 96.18% stake in the company. Shares short for IMNM as of 1763078400 were 14324512 with a Short Ratio of 9.63, compared to 1760486400 on 15236576. Therefore, it implies a Short% of Shares Outstanding of 14324512 and a Short% of Float of 16.280001.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.51 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.9 and -$2.41 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$2.58, with 10.0 analysts recommending between -$1.93 and -$3.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for IMNM’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $6.9M, resulting in an average revenue estimate of $7.78M. In the same quarter a year ago, actual revenue was $9.04M
